News/ News/ Oncology AbbVie signs $2.9bn deal with I-Mab for ‘don’t eat me’ cancer drug Phil Taylor AbbVie, I-Mab, immuno-oncology, licensing, Oncology 0 Comment AbbVie has claimed rights to an immuno-oncology antibody from I-Mab in what is thought to be a record Share X AbbVie signs $2.9bn deal with I-Mab for ‘don’t eat me’ cancer drug https://pharmaphorum.com/news/abbvie-signs-2-9bn-deal-with-i-mab-for-dont-eat-me-cancer-drug/
AbbVie, I-Mab, immuno-oncology, licensing, Oncology
0 Comment
